Black Diamond Therapeutics (Black Diamond Therapeutics) Equity-to-Asset : 0.74 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Black Diamond Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $116.74 Mil. Black Diamond Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $158.57 Mil.

The historical rank and industry rank for Black Diamond Therapeutics's Equity-to-Asset or its related term are showing as below:

BDTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83 Med: 0.74 Max: 0.93
Current: 0.74

During the past 7 years, the highest Equity to Asset Ratio of Black Diamond Therapeutics was 0.93. The lowest was -0.83. And the median was 0.74.

BDTX's Equity-to-Asset is ranked better than
59.16% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs BDTX: 0.74

Black Diamond Therapeutics Equity-to-Asset Historical Data

The historical data trend for Black Diamond Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics Equity-to-Asset Chart

Black Diamond Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-0.30

0.93

0.79

0.74

Black Diamond Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.74	0.72	0.69	0.78	0.74

Competitive Comparison of Black Diamond Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Black Diamond Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's Equity-to-Asset falls into.

Black Diamond Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Black Diamond Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	116.736	/	158.567
	=

Black Diamond Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	116.736	/	158.567
	=

Black Diamond Therapeutics (NAS:BDTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Black Diamond Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Black Diamond Therapeutics (Black Diamond Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.blackdiamondtherapeutics.com

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.

Executives

Biotech Growth N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Ra Capital Nexus Fund, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani	director, 10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein	director, officer: See Remarks	OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov	officer: CHIEF MEDICAL OFFICER	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck	officer: CHIEF SCIENTIFIC OFFICER	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon	director
Mark A. Velleca	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Brent Hatzis-schoch	officer: See Remarks	C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451